What is the current stock price of Northwest Biotherapeutics, Inc. (NWBO)?

As of the latest market data, Northwest Biotherapeutics, Inc. (NWBO) is trading at $0.20. The stock has seen a loss of 0.00% today.

Does Northwest Biotherapeutics, Inc. (NWBO) pay a dividend?

Based on current data, Northwest Biotherapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Northwest Biotherapeutics, Inc.?

The current market capitalization of Northwest Biotherapeutics, Inc. (NWBO) is approximately unavailable.

NWBO

Northwest Biotherapeutics, Inc.·Healthcare

0.20

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.2052W H: $0.48

NWBO NEWS

defenseworld.net

Apr 1

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.25 and traded as low as $0.1950. Northwest Biotherapeutics shares last traded at $0.2065, with a volume of 2,140,465 shares. Northwest Biotherapeutics Price Performance The company's

defenseworld.net

Jan 18

Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Northwest Biotherapeutics and

Company Profile

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2001-12-14

Beta

-0.77

Websitewww.nwbio.com↗